期刊文献+

Ⅱ型糖尿病患者血清脂联素水平的测定及临床意义 被引量:1

下载PDF
导出
摘要 目的:检测Ⅱ型糖尿病患者血清脂联素(adiponectin,APN)含量,探讨其临床应用价值。方法:对38例Ⅱ型糖尿病患者和30例正常者(对照组)采用ELISA法,进行血清脂联素水平检测。结果:Ⅱ型糖尿病患者血清脂联素水平降低,与正常对照组比较,具有显著性差异(P<0.01)。结论:Ⅱ型糖尿病患者血清脂联素水平明显降低,提示:血清脂联素测定,可作为Ⅱ型糖尿病的辅助诊断、治疗及疗效观察。
出处 《医学理论与实践》 2008年第11期1333-1333,共1页 The Journal of Medical Theory and Practice
  • 相关文献

参考文献5

二级参考文献76

  • 1刘军,陈影,刘芳,姚庆姑,许火根,澎名淑,郭瑜琳,陈钦达.2型糖尿病家系非糖尿病一级亲属脂联素水平与胰岛素抵抗和动脉粥样硬化相关性研究[J].中华内分泌代谢杂志,2004,20(3):215-216. 被引量:30
  • 2卢慧玲,王宏伟,张木勋,林汉华.2型糖尿病患者血浆脂联素和抵抗素水平的测定及意义[J].中国动脉硬化杂志,2004,12(3):336-338. 被引量:20
  • 3朱麒钱,尤巧英,李成江,李红,沈建国,斯徐伟,官莉莉,俞钟明,楼大均,金华伟.C反应蛋白与2型糖尿病大血管病变危险因素的相关性研究[J].中华内分泌代谢杂志,2005,21(4):320-321. 被引量:104
  • 4Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res, 2000,32:47-50.
  • 5Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation, 2000,102:1296-1301.
  • 6Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000,96:1723-1732.
  • 7Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem, 2002,277:37487-37491.
  • 8Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem, 2002,277:25863-25866.
  • 9Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun, 1999,257:79-83.
  • 10Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 2000,20:1595-1599.

共引文献170

同被引文献31

  • 1International Diabetes Federation. IDF Diabetes Atlas,56th[EB/OL).[2013-12-10).http://www.idf.org/sites/default/files/EN _ 6E_Atlas_ FulI_O.pdf.
  • 2PhRMA. Report (20 (3): Medicines in development for older Americans[RlOL ).[2013-12-1 O).http://www.phrma. org/sites/defaultl files/pdf/oac20 13.pdf.
  • 3PhRMA.2014 Report: Medicines in Development for Diabetes[R/ OL).[20 14-02-20).http://www. phrma.org/ sites/default/ files/pdf/ diabetes2014.pdf.
  • 4Toscano D. The market for type 2 diabetes therapeutics - dey findings from a recent analysis of global drug development efforts[EB/OL).[20 14-0 1-IS].http://www.drugdeliverytech.com/Main/Back-Issues/ MARKET-BRLEF- The-Market-for- Type-2-Diabetes- Therap-64I.aspx.
  • 5Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen,CD26[J].Science, 1993,261(5120):465-469.
  • 6Ghatak S B, Patel D S, Shanker N, et al. Alogliptin: a novel molecule for improving glycemic control in type U diabetes mellitus[J].Curr Diabetes Rev,20 I 0,6(6):41 0-421.
  • 7White W B, Cannon C P, Heller S R, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J].N Engl J Med,2013,369(14): 1327-1335.
  • 8Novartis International AG. Novartis Q3 and 9M 2013 Condensed Interim Financial Report - Supplementary Data[EB/OL).[20 13-1 0- 21].http://www.novartis.com/downloads/investorsifinanciaI-resultsi quarterly-resultsl20 13-1 O-interim-financial-report-en.pdf.
  • 9Holst J 1. The physiology of glucagon-like peptide I[J].Physiol Rev,2007,S7(4): 1409-1439.
  • 10Jimenez-Solem E,Rasmussen M H,Christensen M. Dulaglutide,a long-acting GLP-I analog fused with an Fe antibody fragment for the potential treatment of type 2 diabetes[J].Curr Opin Mol Ther,20 I 0, 12(6):790-797.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部